JPRN-jRCT2031220073已完成1 期
A Phase I, Single-dose Study with SB206 in Healthy Japanese Adults
Tsubouchi Ichiro0 个研究点目标入组 20 人开始时间: 2022年5月19日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 40age old（—）
- 性别
- Male
入选标准
- •1. Healthy Japanese adult males aged 20 to 40 years at the time of obtaining written informed consent
- •2. Subjects with a body mass index (BMI) of 18.5 to 25.0 at screening
- •3. Subjects who are considered by the investigator or subinvestigator as acceptable for inclusion in the study as judged from the results of observation and examination upon screening and hospitalization
- •4. Subjects who received full explanations regarding the objective of the study, details of the study and the study drug and provided voluntary written informed consent
排除标准
- •1. Subjects with a history of drug allergy
- •2. Subjects with a history of food allergy
- •3. Subjects with a history of contact dermatitis, such as adhesive tape dermatitis, or mechanical urticaria
- •4. Subjects considered ineligible for the study by the investigator or subinvestigator
研究者
相似试验
撤回
1 期
A Phase 1 Single Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EARLI-001ACTRN12622001571763Earli Pty. Ltd.10
已完成
1 期
A Phase 1 Study Evaluating Safety and Tolerability of NVN1000 GelAcne VulgarisNCT01844739Novan, Inc.30
已完成
1 期
A Phase 1 study of S-217622COVID-19JPRN-jRCT2031210202agata Tsutae201
招募中
1 期
To Evaluate the Comparative Pharmacokinetics of Orally Administered EQ143 in Caucasian and Ethnic Chinese PopulationsACTRN12621000848808EQRx, Inc30
已完成
不适用
A phase 1 single ascending dose study in healthy subjects to evaluate safety, tolerability, and pharmacokinetics of XVR011COVID-1910047438NL-OMON49939ExeVir Bio BV30